Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 With Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma

Investigators used CRISPR/Cas9 deletion of the CD38 gene in T cells and developed DCAR, a double CAR system targeting CD38 and CS1 through activation and co-stimulation receptors, respectively.